

Zydus receives final approval from the USFDA for Chlorthalidone Tablets USP

Ahmedabad, 13 May, 2019

Zydus Cadila has received the final approval from the USFDA to market Chlorthalidone Tablets USP (US RLD – THALITONE[®]), 25 mg and 50 mg. Chlorthalidone is used to treat high blood pressure (hypertension). It is also used to treat fluid retention (edema) in people with congestive heart failure, cirrhosis of the liver or kidney disorders or edema caused by taking steroids or estrogen. It will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad.

The group now has 266 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 23,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.
